Pharma Tech

Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal

Oct 28, 2026, 11:06 AM

Read Full Article → Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal

Translate article text

Choose a language and wait for the translated text.

Astellas pens this immuno-oncology deal with Audax as it looks to offset the upcoming patent expiry of key portfolio medicine, Xtandi.